Cellectis shifts CAR-T manufacturing in-house, boosts efficacy compared to third-party CDMOs: #ASH23 news2023-12-07T17:28:37+00:00December 7th, 2023|Endpoints News|
ADC manufacturing will likely stay with established CDMOs due to high barrier to market entrynews2023-12-07T17:00:09+00:00December 7th, 2023|Endpoints News|
Three big winners from AbbVie’s $8.7B Cerevel deal: A drugmaker, a CEO and a SPACnews2023-12-07T16:12:56+00:00December 7th, 2023|Endpoints News|
Allen Institute and Chan Zuckerberg Initiative launch research center to probe mysteries of the cellnews2023-12-07T16:00:36+00:00December 7th, 2023|Endpoints News|
Biden administration lays foundation for use of march-in rights as it talks up drug price goalsnews2023-12-07T15:57:02+00:00December 7th, 2023|Endpoints News|
Sanofi R&D day: CEO Paul Hudson touts 12 blockbusters, ups R&D spendnews2023-12-07T15:55:19+00:00December 7th, 2023|Endpoints News|
AbbVie bets that nearly $20B in deals can bring it into the post-Humira futurenews2023-12-07T15:49:10+00:00December 7th, 2023|Endpoints News|
Merck details PhII TIGIT/PD-1 fail in lung cancernews2023-12-07T12:15:26+00:00December 7th, 2023|Endpoints News|
Updated: 89bio prices $150M public offering for PhIII development of NASH drugnews2023-12-07T12:04:31+00:00December 7th, 2023|Endpoints News|
Artbio raises $90M as radiopharma field finds its footingnews2023-12-07T12:00:44+00:00December 7th, 2023|Endpoints News|
